# Black Diamond Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/black-diamond-therapeutics

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.blackdiamondtherapeutics.com
- Total disclosed funding: $148M
- Latest round: Series C (Dec 5, 2019)
- Investors on record: 15

## About

Black Diamond Therapeutics, Inc. is focused on developing innovative therapies to treat genetically defined cancers, particularly non-small cell lung cancer and glioblastoma, utilizing its proprietary MasterKey approach to target oncogenic mutations.Founded in 2014 and headquartered in Cambridge, US, Black Diamond Therapeutics, Inc. specializes in oncology therapeutics. The company's founders, Elizabeth Buck and Garry Menzel, brought extensive expertise in drug development. As of June 28, 2023, Black Diamond has raised a total of USD 75.00 mn in a Private Placement, which is part of its ongoing funding strategy, with a total of 5 deals completed since its inception.Black Diamond Therapeutics develops therapies targeting non-small cell lung cancer (NSCLC) and glioblastoma (GBM) using its MasterKey approach. Its products, including Silevertinib for NSCLC and GBM, as well as candidates like BDTX-4933 and BDTX-4876, are aimed at overcoming drug resistance and minimizing side effects. The company serves healthcare providers and research institutions primarily in North America, Europe, and select regions in Asia where these cancers are prevalent.In 2020, Black Diamond Therapeutics reported no revenue, with an EBITDA of USD -78.78 mn for the year 2024. The company generates revenue through partnerships with pharmaceutical firms and healthcare institutions, focusing on milestone payments and royalties tied to the success of its innovative therapies.Following its recent funding round on June 28, 2023, in which Black Diamond Therapeutics raised USD 75 mn, the company plans to utilize these funds to expand its product offerings and grow its business operations. The firm is focused on launching new therapies and expanding into additional geographic markets by the end of 2024. The recent funding will support these initiatives, enhancing their capabilities in developing targeted cancer treatments.

## Funding rounds

- Series C, Dec 5, 2019, $85M — New Enterprise Associates, Versant Ventures, Invus [DUP], Wellington Management, Nextech, Roche Venture Fund, Casdin Capital, City Hill Ventures, Deerfield Management, BVF Partners, RA Capital Management, Perceptive Advisors, Boxer Capital, Janus Henderson Investors, Logos Capital
- Series B, Dec 21, 2018, $43M — New Enterprise Associates, Versant Ventures, Invus [DUP], Nextech, RA Capital Management, Perceptive Advisors
- Series A, Dec 11, 2018, $20M — Versant Ventures

## Investors

- Versant Ventures (https://capitalatlas.ai/funds/versant-ventures) — Series A, Series B, Series C
- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series B, Series C
- Invus [DUP] — Series B, Series C
- Nextech (https://capitalatlas.ai/funds/nextech) — Series B, Series C
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series B, Series C
- Perceptive Advisors (https://capitalatlas.ai/funds/perceptive-advisors) — Series B, Series C
- Wellington Management (https://capitalatlas.ai/funds/wellington-management) — Series C
- Roche Venture Fund (https://capitalatlas.ai/funds/roche-venture-fund) — Series C
- Casdin Capital (https://capitalatlas.ai/funds/casdin-capital) — Series C
- City Hill Ventures (https://capitalatlas.ai/funds/city-hill-ventures) — Series C
- Deerfield Management (https://capitalatlas.ai/funds/deerfield-management) — Series C
- BVF Partners (https://capitalatlas.ai/funds/bvf-partners) — Series C
- Boxer Capital (https://capitalatlas.ai/funds/boxer-capital) — Series C
- Janus Henderson Investors — Series C
- Logos Capital (https://capitalatlas.ai/funds/logos-capital) — Series C